Apollo Biowellness Executes Letter Of Intent with Medwell AI, Inc.

Core Insights - Apollo Biowellness, Inc. has signed a Letter of Intent to establish a vertically integrated health, wellness, and longevity platform [1] - New MedWell Ai, Inc. will operate across three divisions: national pharma distribution and telemedicine, surgical and cosmetic centers, and advanced biologics [3] - The consolidated company is projected to exceed $25 million in annual revenues for 2026, based on trailing revenues of $14 million in 2025, with conservative EBITDA margins of at least 20% [4] Company Developments - The CEO of MedWell Ai, Steve Rubakh, emphasized the creation of a comprehensive wellness ecosystem aimed at reducing supply chain inefficiencies and enabling national expansion [5] - The company is also considering additional strategic acquisitions to enhance its position in the regenerative wellness sector [5] Market Overview - The global regenerative medicine market was valued at approximately $35.5 billion in 2024 and is expected to reach over $169 billion by 2034, growing at a CAGR of roughly 16% to 23% [8] - The broader global wellness economy reached $6.3 trillion in 2023 and is forecasted to grow to $9.8 trillion by 2029 [8] - North America is the leading market, accounting for over 58% of the global market share in 2024, with the U.S. market projected to surpass $80 billion by 2033 [8]